Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hutchison MediPharma

Request full access

Hutchison Medi Pharma is an entrepreneurial and China-based drug development company

Huangpu, ChinaFounded 2002Biotech & Life Sciences

About Hutchison MediPharma

Hutchison MediPharma operates as the core research and development engine of HUTCHMED (China) Limited, a commercial-stage biopharmaceutical firm established in 2000. The company was founded as a subsidiary of a company within the CK Hutchison multinational conglomerate. It has since evolved into a publicly-traded entity listed on Nasdaq, the London Stock Exchange's AIM, and the Stock Exchange of Hong Kong. Hutchison MediPharma is strategically focused on the discovery, development, and commercialization of targeted therapies and immunotherapies, primarily for oncology and immunological diseases.

The firm's business model is centered on its fully integrated R&D platform, which has produced a robust pipeline of drug candidates. Revenue is generated through multiple streams, including the marketing and distribution of its own oncology products, partnerships with global pharmaceutical giants, and a commercial platform that also distributes third-party prescription drugs and consumer health products in China. A key component of its strategy involves strategic collaborations for co-development and commercialization, such as partnerships with AstraZeneca, Takeda, and Eli Lilly, which provide upfront payments, milestone fees, and royalties on sales. For instance, the partnership with Takeda for the global commercialization of fruquintinib exemplifies this model.

Hutchison MediPharma has successfully brought multiple drug candidates from in-house discovery to market. Its leading product, fruquintinib (marketed as FRUZAQLA® and ELUNATE®), is a small molecule inhibitor approved for treating certain types of colorectal and gastric cancer in the US, Europe, Japan, and China. The company's pipeline is extensive, featuring over ten clinical-stage candidates and numerous preclinical programs. These candidates target a range of validated and novel biological pathways implicated in cancer and autoimmune disorders, such as MET, VEGFR, FGFR, and BTK. This approach allows for the development of therapies both as standalone agents and in combination with other treatments. In early 2025, the company announced a strategic divestment of a significant stake in a joint venture, Shanghai Hutchison Pharmaceuticals, to raise capital to reinvest into its R&D pipeline, particularly focusing on next-generation antibody-targeted therapy conjugates.

Source: Dealroom company data

Hutchison MediPharma in the Huangpu ecosystem

Live from Dealroom

The Hutchison MediPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

See Hutchison MediPharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.